Risk Factors for Nephrotoxicity Associated with Cisplatin

Almanric, Karine; Marceau, Nathalie; Cantin, Ariane; Bertin, Émilie

doi:10.4212/cjhp.v70i2.1641

Cited by 9 publications

(11 citation statements)

References 16 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Almanric et al showed that ACEI/ARBs were used in 29/80 patients (36%), and taking an ACEI or an ARB resulted in an increase of 12.1 µmol/L (95% CI: –15.0, 39.2) in the SCr level, but this increase was found to be statistically insignificant in a multivariate linear and logistic regression analyses. 21 This result was different from our study. This difference may be explained by the possibility that the CIA criteria were different in each study, or that the research population only with stage 4 nonsmall-cell lung cancer or with different tumor types was different.…”

Section: Discussioncontrasting

confidence: 99%

The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly

Liu¹,

Cai²,

Wang³

et al. 2018

TCRM

View full text Add to dashboard Cite

ObjectivesThe most serious adverse reaction of cisplatin is acute kidney injury (AKI). Cisplatin-induced acute kidney injury (CIA) has no specific preventive measures. This study aims to explore the characteristics and risk factors for CIA in the elderly and to identify potential methods to reduce CIA.Materials and methodsPatients ≥18 years old, with primary tumors, who received initial cisplatin chemotherapy and whose serum creatinine (SCr) values were measured within 2 weeks pre- and postcisplatin treatment and who had complete medical records, were selected from a single center from January 1, 2013 to December 31, 2015. The exclusion criteria included radiotherapy or surgery, recurrent tumors, previous cisplatin treatment, lack of any SCr values before or after cisplatin therapy, and incomplete medical records.ResultsOut of a total of 527 patients, 349 were elderly. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) use (9.2%) was more prevalent in the elderly than in younger patients (2.8%, p = 0.007). The dosage of cisplatin treatment was lower in the elderly, but the incidence of CIA (9.46%) was higher in the elderly than in younger patients (3.37%). There were significant differences in the SCr levels, estimated glomerular filtration rate, ACEI/ARB use, and whether a single application of cisplatin was administered, between the elderly AKI group and the non-AKI group. Multivariable analysis showed that administration of a single application of cisplatin (OR 2.853, 95% CI: 1.229, 6.621, p = 0.015) and ACEI/ARB use (OR 3.398, 95% CI: 1.352, 8.545, p = 0.009) were predictive factors for developing CIA in the elderly.ConclusionThe incidence of CIA in the elderly was higher than in younger patients. ACEI/ ARB usage and administration of a single application of cisplatin were independent risk factors for CIA in the elderly.

show abstract

Section: Discussioncontrasting

confidence: 99%

The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly

Liu¹,

Cai²,

Wang³

et al. 2018

TCRM

View full text Add to dashboard Cite

show abstract

“…However, in the literature, it is estimated that there is no significant correlation between the number of cures and the onset of nephrotoxicity. 20 Similarly, De Jongh et al 6 reported that the incidence of nephrotoxicity gradually increased with age (OR ¼ 1.03 year À 1; p ¼ 0.007). In the study of Almanric et al, 20 age (p ¼ 0.032) had a statistically significant impact; each year there was an additional increase in serum creatinine; however, gender and dose of cisplatin were not associated with nephrotoxicity, which is consistent with our results gender (p ¼ 0.47), dose of cisplatin (p ¼ 0.089) and age (p ¼ 0.008).…”

Section: Discussionmentioning

confidence: 94%

“…20 Similarly, De Jongh et al 6 reported that the incidence of nephrotoxicity gradually increased with age (OR ¼ 1.03 year À 1; p ¼ 0.007). In the study of Almanric et al, 20 age (p ¼ 0.032) had a statistically significant impact; each year there was an additional increase in serum creatinine; however, gender and dose of cisplatin were not associated with nephrotoxicity, which is consistent with our results gender (p ¼ 0.47), dose of cisplatin (p ¼ 0.089) and age (p ¼ 0.008). On the other hand, Kumaki et al 18 showed no significant association between cisplatin dose (OR ¼ 1.29, p ¼ 0.14) or age (OR ¼ 1, p ¼ 0.87) and nephrotoxicity.…”

Section: Discussionmentioning

confidence: 94%

Toxicity, risk factors and management of cisplatin-induced toxicity: A prospective study

Ayed

Said

Hamdi

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background and propose Cisplatin is a cytotoxic drug that triggers several toxicities. However, nephrotoxicity and ototoxicity remain major clinical limitations. The aim of our study was to evaluate the incidence of chemotherapy toxicity induced by cisplatin and to analyze the influence of risk factors in the Tunisian population. Methods We performed a prospective descriptive study in a period of four months. Patients were eligible if they had pathologically confirmed malignancies and treated with cisplatin-regimen chemotherapy. Nephrotoxicity and digestive toxicity were graded according to the World Health Organization toxicity scale and ototoxicity was scored clinically according to the Common Terminology Criteria for Adverse Events (CTCAE). Multivariate logistic regression analysis was performed to evaluate the influence of clinical variables on cisplatin-induced toxicity. Results A total of 150 patients were included. Forty-four percent of patients developed cisplatin-regimen toxicity: 15% developed cisplatin-induced nephrotoxicity, 9% cisplatin-induced ototoxicity and 27% digestive toxicity. In the multivariate analysis, age >65 years (OR= 6.129, p = 0.010), metastatic cancer (OR = 0.171, p = 0.007) and cumulative dose (OR= 1.004 mg/m2; p = 0.042) were strong predisposing factors for CDDP-induced nephrotoxicity. The cumulative dose was an independent prognostic indicator for digestive toxicity (OR = 0.997, p = 0.002). Conclusion In our study, age >65 years and metastatic cancer were risk factors for cisplatin-induced nephrotoxicities. We also found the correlation between cumulative dose and nephrotoxicity or digestive toxicity.

show abstract

“…That is why no significant changes in creatinine are observed in case of the patients treated with Manchester RT, revealing a better overall status than the remaining patients. The reason why a decrease in the creatinine levels is not evident in CHRT may be the use of cisplatin-based chemotherapy-this drug is nephrotoxic and tends to increase the creatinine levels [48].…”

Section: Discussionmentioning

confidence: 99%

NMR-Based Metabolomics in Investigation of the Radiation Induced Changes in Blood Serum of Head and Neck Cancer Patients and Its Correlation with the Tissue Volumes Exposed to the Particulate Doses

Boguszewicz

Bieleń

Ciszek

et al. 2021

IJMS

View full text Add to dashboard Cite

In the present study, we analyze the nuclear magnetic resonance (NMR) blood serum metabolic profiles of 106 head and neck squamous cell carcinoma (HNSCC) patients during radio (RT) and concurrent radio-chemotherapy (CHRT). Four different fractionation schemes were compared. The blood samples were collected weekly, from the day before the treatment until the last week of CHRT/RT. The NMR spectra were acquired on A Bruker 400 MHz spectrometer at 310 K and analyzed using multivariate methods. Seven metabolites were found significantly to be altered solely by radiotherapy: N-acetyl-glycoprotein (NAG), N-acetylcysteine, glycerol, glycolate and the lipids at 0.9, 1.3 and 3.2 ppm. The NMR results were correlated with the tissue volumes receiving a particular dose of radiation. The influence of the irradiated volume on the metabolic profile is weak and mainly limited to sparse correlations with the inflammatory markers, creatinine and the lymphocyte count in RT and the branched-chain amino-acids in CHRT. This is probably due to the optimal planning and delivery of radiotherapy improving sparing of the surrounding normal tissues and minimizing the differences between the patients (caused by the tumor location and size).

show abstract

Risk Factors for Nephrotoxicity Associated with Cisplatin

Abstract: Background: Cisplatin-induced nephrotoxicity occurs in about one-third of patients who receive this chemotherapy drug. In late 2012, the study institution began measuring serum creatinine on day 7 after administration of cisplatin to identify patients with acute renal failure.

Cited by 9 publications

References 16 publications

The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly

The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly

Toxicity, risk factors and management of cisplatin-induced toxicity: A prospective study

NMR-Based Metabolomics in Investigation of the Radiation Induced Changes in Blood Serum of Head and Neck Cancer Patients and Its Correlation with the Tissue Volumes Exposed to the Particulate Doses

Contact Info

Product

Resources

About